Original Articles
Vol. 61 No. 2 (2009)
https://doi.org/10.4081/reumatismo.2009.107

Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
2146
Views
1326
Downloads

Authors

R. Scrivo
office@pagepress.org
, Italy.
F. Conti
, Italy.
F.R. Spinelli
, Italy.
S. Truglia
, Italy.
L. Magrini
, Italy.
M. Di Franco
, Italy.
F. Ceccarelli
, Italy.
G. Valesini
, Italy.
The treatment of rheumatoid arthritis (RA) has evolved over the past decade with the introduction of anti-tumor necrosis factor (TNF) α agents, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing joint destruction (1-3). However, some patients do not respond or show suboptimal response to the currently available anti- TNFα agents (infliximab, etanercept, and adalimumab) used either as monotherapy or in combination with methotrexate. Furthermore, patients who respond initially may lose efficacy over time (4) or develop adverse events.

Downloads

Download data is not yet available.

How to Cite



1.
Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo [Internet]. 2009 Jun. 30 [cited 2026 Sep. 12];61(2):107-1. Available from: https://www.reumatismo.org/reuma/article/view/reumatismo.2009.107

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.